We report a novel *ATXN1-NUTM1* gene fusion in a primitive brain tumor (Fig [1](#Fig1){ref-type="fig"}a). A 21-year-old woman was seen in an emergency department for symptoms of increased intracranial pressure, visual disturbance and right hemiparesis. She reported unusual headaches for the past 3 weeks. MRI showed a frontal tumor with intratumoral hemorrhage (Fig. [1](#Fig1){ref-type="fig"}b). The entire tumor was surgically removed. The patient did not receive any additional treatment. 16 months after surgery, the patient was symptom-free and MRI showed no recurrence of the tumor. Fig. 1*ATXN1-NUTM1* gene fusion, confirmed by RT-PCR and Sanger sequencing (**a**). MRI identified a frontal mass. Enhancement after contrast injection (T1) (**b**). Representative histopathology. On the left, loose area with neuron-like tumor cells (\*detail). On the right, increase in cell density (**c**). Fascicular architecture with three mitoses (arrows) (**d**). Chondroid-like, myxoid and hyalinized areas were observed (**e**). Undifferentiated cells with large nucleoli in a chondromyxoid background (**f**). Strong GFAP staining was observed. Tumor showed vascular proliferation (**g**). Neurofilament staining circumscribed the tumor mass with no significant staining within the tumor (**h**). p53 accumulated in tumor nuclei (**i**). Anti-NUT antibody staining showing homogeneous intranuclear expression (**j**)

Histological features were characterized by a fascicular architectural pattern and chondro-myxoid areas (Fig. [1](#Fig1){ref-type="fig"}c, d, e, f). Neuron-like tumor cells were apparent (Fig. [1](#Fig1){ref-type="fig"}c). Mitotic activity was overall low but increased in some foci (Fig. [1](#Fig1){ref-type="fig"}d). Strong GFAP staining led to an initial diagnosis of an unclassified glioneuronal tumor in spite of olig2 and PS100 negativity (Fig. [1](#Fig1){ref-type="fig"}g). Microscopically, the tumor was well circumscribed (Fig. [1](#Fig1){ref-type="fig"}h). p53 was accumulated (Fig. [1](#Fig1){ref-type="fig"}i). CD56 was strongly expressed. TTF1, chromogranin, synaptophysin, CD34, p63, CK5/6 and smooth muscle actin were negative. ATRX, INI1 and BRG1 expression was maintained. Using the Heidelberg DNA methylation-based CNS tumor classifier, no class prediction was obtained with a greater than ≥0.9 confidence threshold \[[@CR1]\]. The closest entity was the CNS Ewing Family Tumor *CIC* group with a score of 0.235 (Additional file [1](#MOESM1){ref-type="media"}: Table S1) (Case methylation data: <http://www.ncbi.nlm.nih.gov/geo>; GSE138550). This tumor group is associated to the *CIC-NUTM1* gene fusion \[[@CR6]\]. We observed strong homogeneous nuclear staining with an anti-NUT antibody, suggesting the presence of a *CIC-NUTM1* fusion (Fig. [1](#Fig1){ref-type="fig"}j). RNA sequencing using the Illumina TruSight RNA Fusion panel and Manta for fusion calling revealed a novel *ATXN1-NUTM1* fusion. A *CIC-NUTM1* fusion was not detected. *ETV4* was overexpressed as in CIC-fused sarcomas \[[@CR4], [@CR6]\]. No pathogenic variants were observed in tumor DNA using a 571-gene targeted sequencing panel (Additional file [2](#MOESM2){ref-type="media"}: Table S2).

The fusion gene transcript encompassed almost all of the *ATXN1* coding sequence and the entire exon 6, 7 and 8 regions of *NUTM1*. The most common *NUTM1* breakpoints map between exon 1 and 2, but breakpoints at the distal end of exon 5 have also been described in some *CIC-NUTM1* sarcomas \[[@CR4]\].

Initially associated with NUT midline carcinomas, *NUTM1* fusions have now been described in a broad spectrum of tumors ranging from carcinoma to sarcoma and leukemia \[[@CR2], [@CR3], [@CR7]\]. The most common fusion partner gene in carcinoma and sarcoma is *BRD4* followed by *BRD3* and *NSD3*. Various new partners have been recently described \[[@CR2], [@CR3], [@CR5]\]. The prognosis of these tumors is generally poor, although NUT-associated leukemias appear to be associated with a better prognosis and *YAP1-NUTM1* is associated with benign skin adnexal gland tumors \[[@CR3], [@CR5]\].

*CIC* rearranged sarcomas are often fused to *DUX4* and less frequently to *NUTM1* \[[@CR4], [@CR7]\]. All *CIC* re-arranged tumors irrespective of their location or their fusion partner gene share the same transcriptomic profile defining a molecular subgroup distinct from NUT carcinoma \[[@CR4], [@CR7]\]. Interestingly, *ATXN1* codes for ataxin1 which forms a transcriptional repressor complex with CIC. They are both part of the CIC-ATXN1-ATXN1L mitotic cell cycle regulator axis \[[@CR8]\]. Excluding *CIC-NUTM1* fused tumors, only one *NUTM1* rearranged brain tumor has been previously reported, namely a cytokeratin negative *BRD4-NUTM1* PNET-like parietal lobe tumor in a 3-year old boy with GFAP and synaptophysin positivity. On methylation profiling, this neoplasm did not cluster with tumors of the CNS Ewing Family Tumor *CIC* group \[[@CR2]\].

Myxoid and chondroid differentiation has been reported in *NUTM1*-rearranged sarcomas but is unusual in primary glioneuronal tumors. Whether the strong GFAP positivity of our specific case is indicative of a glial tumor or of a sarcoma with myoepithelial differentiation cannot be assessed due to the lack of positive staining and specificity for other markers tested. GFAP positivity has been described in 3 out of 4 *NUTM1* rearranged soft tissue or visceral sarcomas, this is in contrast to the CNS Ewing Family Tumor *CIC* group which fails to express any differentiation markers \[[@CR2], [@CR6]\]. We recommend performing NUT immunohistochemistry followed by RNA sequencing to identify any potential *NUTM1* fusion partner genes in GFAP+/olig2- unclassified glioma, particularly those with myxoid and/or chondroid features. The *ATXN1*-*NUTM1* fusion gene may define a novel group of rare primary brain tumors. The prognostic influence of *NUTM1* fusion partners and the brain localization of *NUTM1*-rearranged tumors warrant further investigation.
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**Additional file 1: Table S1.** Results of the Heidelberg DNA methylation-based CNS tumor classifier (entities and scores). **Additional file 2: Table S2.** List of the 517 childhood cancer genes in the dragon targeted gene sequencing panel (Illumina_TruSeq Custom Amplicon).
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